OUP user menu

Journal of Crohn's and Colitis: 9 (5)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

3.562
4.023

Published on behalf of

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Matthieu Allez , Konstantinos Karmiris , Edouard Louis , Gert Van Assche , Shomron Ben-Horin , Amir Klein , Janneke Van der Woude , Filip Baert , Rami Eliakim , Konstantinos Katsanos , Jørn Brynskov , Flavio Steinwurz , Silvio Danese , Severine Vermeire , Jean-Luc Teillaud , Marc Lémann , Yehuda Chowers
DOI: http://dx.doi.org/10.1016/j.crohns.2010.04.004 355-366 First published online: 1 October 2010

Abstract

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.

Keywords
  • Inflammatory bowel diseases
  • Crohn's disease
  • Ulcerative colitis
  • Anti-TNF therapy
  • Immunogenicity
  • Pharmacology
  • Abbreviations
    mAbs
    monoclonal antibodies
    IFX
    infliximab
    ADA
    adalimumab
    CZP
    Certolizumab pegol
    PNR
    primary non response to anti-TNF agent
    LOR
    loss of response to anti-TNF agent
    ATI
    antibodies to infliximab
    ATA
    antibodies to adalimumab
    FcγR
    Fc gamma receptor
    ELISA
    enzyme-linked immunosorbent assays
    RIA
    radio-immunoassays
    ANA
    anti-nuclear antibodies.
  • View Full Text

    Log in through your institution